Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-11
2008-12-16
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S187000
Reexamination Certificate
active
07465746
ABSTRACT:
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 3142699 (1964-07-01), Wagner et al.
patent: 4477389 (1984-10-01), Chen et al.
patent: 6057342 (2000-05-01), Fevig et al.
patent: 6440686 (2002-08-01), Sakowicz
patent: 2005/0038074 (2005-02-01), Coleman et al.
patent: 2005/0043357 (2005-02-01), Coleman et al.
patent: 2005/0119484 (2005-06-01), Breslin et al.
patent: 2005/0176776 (2005-08-01), Coleman et al.
patent: 2005/0203110 (2005-09-01), Coleman et al.
patent: 2005/0234080 (2005-10-01), Coleman et al.
patent: 2006/0100191 (2006-05-01), Breslin et al.
patent: 2006/0135594 (2006-06-01), Fraley et al.
patent: 2006/0142278 (2006-06-01), Coleman et al.
patent: 2006/0223844 (2006-10-01), Coleman
patent: 2006/0287302 (2006-12-01), Coleman et al.
patent: WO 93/20099 (1993-10-01), None
patent: WO 98/06694 (1998-02-01), None
patent: WO 03/049527 (2003-06-01), None
patent: WO 03/105855 (2003-12-01), None
patent: WO 03/106417 (2003-12-01), None
patent: WO 2004/037171 (2004-05-01), None
Commercial Boronic Acids (created by examiner).
Commercial 1-1 (created by examiner).
Commercial 4-piperidinones (created by examiner).
Hutchins, R.O. et. al. J. Org. Chem. 1977, 42, 82-91.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim Preface p. IX, Chapter 8, pp. 279-309.
(“Lithium Aluminum Hydride” Paquette, L. in Encyclopedia of Reagents for Organic Synthesis Online Posting Date: Oct. 15, 2004 John Wiley & Sons, Ltd. “http://www.mrw.interscience.wiley.com/eros/articles/rl036/frame.html”.
Bachmann et. al. Macromolecular Chemistry and Physics 2001, 202, 3410-3419.
Mark E. Fraley, et. al. “Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP” Bioorganic & Medicinal Chemistry Letters 2006, 16, 1775-1779.
Cox et. al. “Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP” Bioorganic & Medicinal Chemistry Letters 2005, 15, 2041-2045.
Henry R. Henze and Charles M. Blair “The Number of Structurally Isomeric Alcohols of the Methanol Series” Journal of the American Chemical Society 1931, 3042.
Patani et. al. “Bioisosterism: A Rational Approach in Drug Design” Chemical Reviews 1996, 96, 3147-3176.
C. Sonesson, et al., J. Org. Chem. 1996, vol. 61, p. 4756-4763.
N. Iwasawa, et al., J. Org. Chem. 1998, vol. 63, p. 3164-3165.
N. Iwasawa, et al., J. Org. Chem. 1997, vol. 62, p. 1918-1919.
R. Mison, et al., J. Chem. Research(S), 1989, 126-127.
O. Yebdri, et al., Bulletin De La Societe Chimique de France, 1983, p. 195-201.
A. Ranjon, Bulletin De La Societe Chimique de France, 1971, p. 2068-2072.
M. Bujard, et al., Tetrahedron Letters, vol. 40, 1999, p. 8785-8788.
M. Carpes, et al., Synlett, No. 7, 2000, p. 1037-1039.
A. Boukhari, et al., J. Cryst. Spect. Res., vol. 19, Iss. 3, 1989, p. 603-621.
C. Cox, et al., Bioorganic & Medicinal Chem Ltrs. vol. 15, pp. 2041-2045 (2005), “Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP”.
W. Tao, Cell Cycle, vol. 4(11), pp. 1495-1499 (2005), “The mitotic checkpoint in cancer therapy”.
K. D. Chu, et al., Proc. Am. Soc. Clin. Oncol., abstract 525, p. 131 (2003), “A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts) with solid tumors”.
R. Sakowicz, et al., Cancer Research, vol. 64, pp. 3276-3280 (2004), “Antitumor activity of a kinesin inhibitor”.
W. Tao, et al., Cancer Cell, vol. 8, pp. 49-59 (2005), “Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage”.
M. Fraley, et al., Bioorganic & Medicinal Chem Ltrs., vol. 16, pp. 1775-1779 (2006), “Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitiotic kinesin KSP”.
R. Garbaccio, et al., Bioorganic & Medicinal Chem Ltrs., vol. 16, pp. 1780-1783 (2006), “Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility”.
C. Cox, et al., Bioorganic & Medicinal Chem Ltrs., vol. 16, pp. 3175-3179 (2006), “Kinesin spindle protein (KSP) inhibitors. Part 4:1 Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP”.
Coleman Paul J.
Cox Christopher D.
Garbaccio Robert M.
Hartman George D.
Beeler Nicole M.
Desai Rita
Merck & Co. , Inc.
Muthard David A.
O'Dell David K
LandOfFree
Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4040804